ArticleThe pharmacogenomics journal2026

Cost-effectiveness analysis of encorafenib in untreated BRAF V600E-mutant metastatic colorectal cancer in China.

Shaohong Luo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.